| Date | Title | Description | |
|---|---|---|---|
| 02 Mar 2021 | On business and financial situation | The Company releases a presentation related to an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States | Download |
| 24 Feb 2021 | About corporate governance | The Company informs about the agreements adopted by the Board of Directors | Download |
| 27 Nov 2020 | On business and financial situation | The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia | Download |
| 09 Jul 2020 | On business and financial situation | ROVI informs on the Collaboration with Moderna for Outside the United States Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 28 Jul 2021 | On business and financial situation | ROVI releases the first half 2021 results presentation | Download |
| 05 Jul 2021 | Liquidity contracts and specialists | Liquidity contract: transactions conducted in the second quarter of 2021 | Download |
| 02 Jul 2021 | Other relevant information | The Company informs about the dividends payment | Download |
| 02 Jul 2021 | Other relevant information | The Company informs about the dividends payment | Download |
| 17 Jun 2021 | Announcement of general shareholders’ meeting | ROVI releases the information related to its General Shareholders Meeting | Download |